Luis Ferran

2.5k total citations · 1 hit paper
5 papers, 1.9k citations indexed

About

Luis Ferran is a scholar working on Clinical Biochemistry, Molecular Biology and Nephrology. According to data from OpenAlex, Luis Ferran has authored 5 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Clinical Biochemistry, 2 papers in Molecular Biology and 1 paper in Nephrology. Recurrent topics in Luis Ferran's work include Advanced Glycation End Products research (3 papers), RNA Interference and Gene Delivery (1 paper) and Natural Antidiabetic Agents Studies (1 paper). Luis Ferran is often cited by papers focused on Advanced Glycation End Products research (3 papers), RNA Interference and Gene Delivery (1 paper) and Natural Antidiabetic Agents Studies (1 paper). Luis Ferran collaborates with scholars based in United States, Germany and Japan. Luis Ferran's co-authors include Ann Marie Schmidt, David M. Stern, Yan Lü, Lisa Park, Kathleen G. Raman, Wing Chow, M. Hofmann, Nozomu Tanji, Brigitte Kohl and Evanthia Lalla and has published in prestigious journals such as Journal of Clinical Investigation, Nature Medicine and Arteriosclerosis Thrombosis and Vascular Biology.

In The Last Decade

Luis Ferran

5 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts

1998 930 citations Lisa Park, Kathleen G. Raman et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Luis Ferran United States	5	1.1k	556	402	317	305	5	1.9k
Marie‐Paule Wautier France	22	989 0.9×	529 1.0×	582 1.4×	129 0.4×	276 0.9×	36	2.5k
Sybille Franke Germany	27	1.2k 1.0×	603 1.1×	731 1.8×	274 0.9×	152 0.5×	63	2.5k
Max H. Stickland United Kingdom	25	638 0.6×	605 1.1×	313 0.8×	81 0.3×	173 0.6×	50	2.5k
Anders Jorsal Denmark	24	382 0.3×	818 1.5×	473 1.2×	116 0.4×	156 0.5×	39	1.9k
Wai Han Yiu Hong Kong	23	260 0.2×	207 0.4×	787 2.0×	223 0.7×	467 1.5×	53	2.1k
Evis Harja United States	17	1.1k 0.9×	424 0.8×	595 1.5×	24 0.1×	369 1.2×	20	2.0k
A.M. Schmidt United States	6	1.3k 1.1×	625 1.1×	564 1.4×	21 0.1×	298 1.0×	6	2.0k
Vera Delaney United States	18	557 0.5×	392 0.7×	321 0.8×	43 0.1×	65 0.2×	43	1.7k
Dariusz Moczulski Poland	19	159 0.1×	302 0.5×	282 0.7×	179 0.6×	66 0.2×	69	1.4k
Christiane Rüster Germany	13	280 0.2×	320 0.6×	313 0.8×	48 0.2×	106 0.3×	21	1.3k

Countries citing papers authored by Luis Ferran

Since Specialization

Citations

This map shows the geographic impact of Luis Ferran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luis Ferran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luis Ferran more than expected).

Fields of papers citing papers by Luis Ferran

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luis Ferran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luis Ferran. The network helps show where Luis Ferran may publish in the future.

Co-authorship network of co-authors of Luis Ferran

This figure shows the co-authorship network connecting the top 25 collaborators of Luis Ferran. A scholar is included among the top collaborators of Luis Ferran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luis Ferran. Luis Ferran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

5 of 5 papers shown

1.

Tsuji, Takemasa, Paul Sabbatini, Achim A. Jungbluth, et al.. (2013). Effect of Montanide and Poly-ICLC Adjuvant on Human Self/Tumor Antigen-Specific CD4+ T Cells in Phase I Overlapping Long Peptide Vaccine Trial. Cancer Immunology Research. 1(5). 340–350. 52 indexed citations

2.

Hofmann, M., Evanthia Lalla, Yan Lü, et al.. (2001). Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. Journal of Clinical Investigation. 107(6). 675–683. 435 indexed citations

3.

Kislinger, Thomas, Nozomu Tanji, Thoralf Wendt, et al.. (2001). Receptor for Advanced Glycation End Products Mediates Inflammation and Enhanced Expression of Tissue Factor in Vasculature of Diabetic Apolipoprotein E–Null Mice. Arteriosclerosis Thrombosis and Vascular Biology. 21(6). 905–910. 238 indexed citations

4.

Park, Lisa, Kathleen G. Raman, Yan Lü, et al.. (1998). Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nature Medicine. 4(9). 1025–1031. 930 indexed citations breakdown →

5.

Miyata, Toshio, Osamu Hori, Jian Zhang, et al.. (1996). The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-beta2microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amyloidosis.. Journal of Clinical Investigation. 98(5). 1088–1094. 247 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact